Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)—In Vitro Testing
Open Access
- 22 December 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 29
Abstract
Bile acids and bile salts (BA/BS) are substrates of both influx and efflux transporters on hepatocytes. Canalicular efflux transporters, such as BSEP and MRP2, are crucial for the removal of BA/BS to the bile. Basolateral influx transporters, such as NTCP, OATP1B1/1B3, and OSTα/β, cooperate with canalicular transporters in the transcellular vectorial flux of BA/BS from the sinusoids to the bile. The blockage of canalicular transporters not only impairs the bile flow but also causes the intracellular accumulation of BA/BS in hepatocytes that contributes to, or even triggers, liver injury. In the case of BA/BS overload, the efflux of these toxic substances back to the blood via MRP3, MRP4, and OST α/β is considered a relief function. FXR, a key regulator of defense against BA/BS toxicity suppresses de novo bile acid synthesis and bile acid uptake, and promotes bile acid removal via increased efflux. In drug development, the early testing of the inhibition of these transporters, BSEP in particular, is important to flag compounds that could potentially inflict drug-induced liver injury (DILI). In vitro test systems for efflux transporters employ membrane vesicles, whereas those for influx transporters employ whole cells. Additional in vitro pharmaceutical testing panels usually include cellular toxicity tests using hepatocytes, as well as assessments of the mitochondrial toxicity and accumulation of reactive oxygen species (ROS). Primary hepatocytes are the cells of choice for toxicity testing, with HepaRG cells emerging as an alternative. Inhibition of the FXR function is also included in some testing panels. The molecular weight and hydrophobicity of the drug, as well as the steady-state total plasma levels, may positively correlate with the DILI potential. Depending on the phase of drug development, the physicochemical properties, dosing, and cut-off values of BSEP IC50 ≤ 25–50 µM or total Css,plasma/BSEP IC50 ≥ 0.1 may be an indication for further testing to minimize the risk of DILI liability.Keywords
This publication has 161 references indexed in Scilit:
- Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytesToxicology and Applied Pharmacology, 2012
- Hepatic Deletion of SIRT1 Decreases Hepatocyte Nuclear Factor 1α/Farnesoid X Receptor Signaling and Induces Formation of Cholesterol Gallstones in MiceMolecular and Cellular Biology, 2012
- Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase–signaling pathwayHepatology, 2011
- Organic anion transporting polypeptide 1a/1b–knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugsJournal of Clinical Investigation, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Mouse Organic Solute Transporter α Deficiency Enhances Renal Excretion of Bile Acids and Attenuates CholestasisHepatology, 2009
- Bile acid transportersJournal of Lipid Research, 2009
- ATP8B1 Deficiency Disrupts the Bile Canalicular Membrane Bilayer Structure in Hepatocytes, But FXR Expression and Activity Are MaintainedGastroenterology, 2009
- Ostα-Ostβ is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liverAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Hepatoprotective role of PXR activation and MRP3 in cholic acid‐induced cholestasisBritish Journal of Pharmacology, 2007